ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

CTOR vs SER // OPERATING MARGIN

Citius Oncology Inc. (NASDAQ) VS. Serina Therapeutics Inc. (NYSE) • 15-METRIC TALLY: CTOR 1 — SER 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CTOR VS. SER) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC CTOR SER SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -11.16% — — TIE /fcf-yield <GO>
Operating Margin ACTIVE — -60.00% — TIE /operating-margins <GO>
Net Profit Margin — -60.00% — TIE /net-margins <GO>
Revenue Growth (YoY) — 132.10% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 1/9 3/9 -2.00 SER /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 29.1 52.3 -23.27 SER /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $49.2M $48.0M $1.2M CTOR /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR CTOR REV SER REV CTOR GROSS % SER GROSS % CTOR FCF SER FCF
FY 2025 $0 $130.0K — — -$5.5M -$18.0M
FY 2024 $0 $56.0K — — $126.4K -$17.2M
FY 2023 $0 $3.2M — — -$601.3K -$2.5M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CTOR // BETA —
SER // BETA —